The BC Centre for Excellence (BC-CfE) Drug Treatment Program (DTP) is an unparalleled world-class clinical registry designed to facilitate access to provincially subsidized antiretroviral therapy (ART) free of cost to participants who are medically eligible persons living with HIV in BC.

After a hiatus caused by the COVID-19 pandemic, the BC-CfE’s award-winning Intensive Preceptorship program has resumed. On May 9th, a small cohort of physicians and nurse practitioners began the first offering of the program since 2019, which will see them gain knowledge, skills, and confidence in providing care to people living with HIV (PLWH).

New BC-CfE research, published in the recent issue of AIDS, characterizes trends in the annual prevalence of drug interactions between antiretroviral therapy (ART) and other non-antiretroviral medications in relation to ART prescribing patterns. The study also describes drug interaction-related ART changes.

Collaborating with colleagues from UBC and UCLA, BC-CfE researchers, in a novel study, looked at whether people living with HIV (PLWH) and (COPD) experience an acceleration of aging in their airways, independent of their smoking history.

In what’s believed to be a first of its kind analysis, BC-CfE researchers evaluated patient reported HIV care experiences and therapeutic outcomes prior to, and after, implementation of BC’s Treatment as Prevention®¨ (TasP®¨) designed Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) program.

Dr. Brumme is an inspiring leader who is full of energy and passion. I had the opportunity to work with her at the start of the pandemic and she has been most helpful and insightful with the research and clinical teams. I look forward to learning more from her.